文献速递垂体与肾上腺疾病

解析奥曲肽与卡麦角林对分泌生长激素及生长激素/催乳素垂体瘤的体外疗效

Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

在23例肢端肥大症患者肿瘤原代培养中头对头比较奥曲肽(OCT)与卡麦角林(CAB)抑制生长激素(GH)分泌的效果,并检测生长抑素(SST)和2型多巴胺(D2R)受体表达。OCT疗效略高于CAB(GH降低-39.5% vs -32.5%,P=0.079),在GH/PRL共分泌瘤中两者效果叠加,SST1和D2R表达更高;SST1是CAB反应的最佳预测指标。

要点

  • OCT抑制GH分泌的疗效较CAB略高(GH降低-39.5% vs -32.5%,P=0.079)。
  • GH/PRL共分泌瘤中两药效果叠加(-42.1% vs -44.8%),SST1和D2R表达高于纯GH瘤。
  • SST1 mRNA表达可预测GH/PRL共分泌瘤对CAB的优先反应(AUC 0.913)。

核心结论

  • 体外实验中OCT比CAB有效5%至10%。
  • SST1 mRNA表达可能是GH/PRL共分泌瘤对CAB治疗优先反应的可信标志物。

研究设计与样本

  • 研究纳入23例来自荷兰鹿特丹Erasmus医学中心的肢端肥大症患者的肿瘤培养物。
  • 评估OCT和CAB(10 nM,处理72小时)对GH分泌的抑制效果,并检测受体mRNA表达。

主要发现

  • OCT较CAB显示略高的疗效(GH降低-39.5% vs -32.5%,P=0.079)。
  • 在GH/PRL共分泌瘤中两药效果叠加(-42.1% vs -44.8%),且SST1和D2R表达高于纯GH分泌瘤(P=0.020和P=0.026)。
  • 23例培养中8例OCT比CAB更有效,3例CAB比OCT更有效(CAB+组)。
  • CAB+组肿瘤中SST1表达高于其他组(P=0.034)。
  • ROC曲线分析显示SST1和D2R可区分GH与GH/PRL共分泌(AUC 0.856,P=0.013;AUC 0.822,P=0.024)。

关键数值与推荐

  • OCT和CAB处理浓度均为10 nM,处理时间72小时。
  • CAB反应定义为GH降低≥50%。
  • SST1预测CAB反应的AUC为0.913(P=0.006),敏感性80%,特异性94%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Cabergoline (CAB) is an off-label medical therapy for acromegaly, overshadowed by first-generation somatostatin receptor ligands, eg, octreotide (OCT). OBJECTIVE: This was a head-to-head comparison between OCT and CAB in inhibiting growth hormone (GH) secretion in primary cultures of GH- and GH/prolactin (PRL)-secreting tumors; we also investigated the role of somatostatin (SST) and dopamine type 2 (D2R) receptor expression. METHODS: We evaluated the antisecretory effect of OCT and CAB, together with receptor mRNA expression, in 23 tumor cultures obtained from acromegaly patients referred to the Erasmus Medical Center (Rotterdam, The Netherlands). GH concentrations in cell culture media were determined after 72-hour OCT and CAB treatment (10 nM). RESULTS: OCT showed a slightly higher efficacy compared with CAB (GH decrease -39.5% vs -32.5%, P = 0.079). The effect of the 2 drugs was superimposable in GH/PRL co-secreting tumors (-42.1% vs -44.8%), where SST1 and D2R had a higher expression compared with the pure GH-secreting tumors (P = 0.020 and P = 0.026). OCT was more effective than CAB in 8/23 cultures, while CAB was more effective than OCT in 3/23 (CAB+ group). In CAB+ tumors, SST1 expression was higher compared with the other groups (P = 0.034). At receiver operating characteristic (ROC) curve analysis, SST1 and D2R discriminated between GH and GH/PRL co-secretion (AUC 0.856, P = 0.013; AUC 0.822, P = 0.024). SST1 was the best predictor of CAB response (≥50% GH reduction, AUC 0.913, P = 0.006; 80% sensitivity, 94% specificity). CONCLUSION: OCT is 5% to 10% more effective than CAB in vitro. SST1 mRNA expression can represent a reliable marker of GH/PRL co-secreting tumors showing a preferential response to CAB treatment.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Gatto F, Feelders RA, van Koetsveld PM, et al. Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH/PRL-Secreting Pituitary Tumors. J Clin Endocrinol Metab. 2023. PMID: 36413489. doi:10.1210/clinem/dgac675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。